Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: Gel compositions containing a Michael addition elastomer formed from the reaction of a reactant molecule containing two or more Michael acceptor groups and a molecule containing one or Michael donor group with two or more active hydrogens in its molecule and capable of forming 1,4-addition products with the Michael acceptor reactants, in a topically acceptable carrier fluid. The gelled compositions may further contain a personal or healthcare active. The actives may be incorporated into the gel via either a pre or post load method.

Abstract: The present disclosure relates to gel compositions of, or containing, a non-isocyanate polyurethane (NIPU) elastomer formed from the reaction of a polycarbonate, where carbonate groups may be cyclic or non-cyclic, and a polyamine, where amines are either primary or secondary, in an optional topically acceptable carrier fluid. The gelled compositions may further contain a personal or healthcare active. The actives may be incorporated into the gel via either a pre or post load method.

Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: A continuous printhead drop deflector system includes a gas flow duct including a wall, the wall including a porous member having pores through which liquid can flow and a liquid flow channel, the flow channel being separated from the air flow duct by the porous member, the flow channel includes; a first port for extracting liquid from a first portion of the liquid flow channel; a second port for supplying liquid to a second portion of the liquid flow channel; one or more paths in the liquid channel permitting fluid to flow from the second portion to the first portion; wherein liquid, supplied through the second port to the second portion of the liquid channel and through the one or more paths to the first portion of the liquid channel, contacts and wicks into the porous member before being extracted through the first port.

Abstract: A continuous printhead drop deflector system includes a gas flow duct including a wall, the wall including a porous member having pores through which liquid can flow and a liquid flow channel, the flow channel being separated from the air flow duct by the porous member, the flow channel includes; a first port for extracting liquid from a first portion of the liquid flow channel; a second port for supplying liquid to a second portion of the liquid flow channel; one or more paths in the liquid channel permitting fluid to flow from the second portion to the first portion; wherein liquid, supplied through the second port to the second portion of the liquid channel and through the one or more paths to the first portion of the liquid channel, contacts and wicks into the porous member before being extracted through the first port.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.

Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.

Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.